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Primary prevention of age related macular degeneration
Current evidence does not support a protective role for dietary antioxidant vitamins 
In this week’s BMJ, Chong and colleagues present a 
 systematic review and meta-analysis of the effectiveness 
of dietary antioxidants, including supplements, in the pri-
mary prevention of age related macular degeneration.1
Age related macular degeneration is one of the most 
important causes of visual loss in older people. The 
number of people affected will increase as populations 
age.2 Two types of age related macular degeneration 
exist. Geographic atrophy is a sharply demarcated area 
of depigmentation caused by atrophy of the retinal 
pigment epithelium; neovascular degeneration occurs 
when new blood vessels grow under the retinal pig-
ment epithelium leading to haemorrhage and scarring. 
Age related macular degeneration is diagnosed in peo-
ple aged 50 or more when no other obvious cause for 
degeneration exists.
New treatments are being developed rapidly. In the 
past two years, intraocular injections of agents that 
interfere with angiogenesis have been licensed for use 
in this condition.3 These bind to vascular endothe-
lial growth factors to prevent endothelial cell prolif-
eration and neovascularisation. Although improved 
treatments are always encouraging for people with age 
related macular degeneration, visual loss arising from 
the growth of new vessels is usually permanent, and 
no effective treatments exist for geographic atrophy. 
Research into why age related macular degeneration 
develops, with a view to preventing it, continues.
The incidence of many diseases increases exponen-
tially with age. One common theory for the aetiology 
of many age related diseases, including age related 
macular degeneration, is that they arise as a result of 
the cumulative effects of oxidative stress.4 The sys-
tematic review by Chong and colleagues summarises 
the results of seven prospective studies and three ran-
domised controlled trials evaluating the association 
between dietary intake of antioxidant vitamins and 
minerals (such as vitamin C, vitamin E, various types 
of carotenoids, and zinc) or dietary supplements (vita-
min E and β carotene) and age related macular degen-
eration.1 This is the first such review of usual dietary 
intake—previous reviews have considered randomised 
controlled trials of supplements.5
The prospective studies show that people with rela-
tively high dietary intakes of antioxidant nutrients are no 
more or less likely to develop the condition than those 
with relatively low intakes. The possible exception to this 
is high dietary intake of vitamin E, which was associated 
with a 20% reduced odds of age related macular degen-
eration. The significance of this finding depended on 
which studies were included in the meta-analysis. Further 
studies are needed to confirm its relevance.
Dietary intake is difficult to measure accurately. In 
observational studies it is difficult to be sure that a 
fair comparison is being made, because people with 
different diets also differ in many other ways. In 
spite of these caveats, evidence of a strong protective 
effect of the dietary antioxidants studied was lacking. 
Obviously, a well balanced diet containing fruit and 
vegetables has many other health benefits and should 
still be recommended. In addition, included studies 
were carried out on relatively well nourished pop-
ulations in the United States, Australia, and Europe, 
and the results may not apply to populations with 
different dietary intakes.
Three randomised controlled trials provide good evi-
dence that vitamin E or β carotene supplements do not 
prevent age related macular degeneration (one of these 
trials is included in abstract form in the review but has 
since been published6). Although generally regarded 
as safe, vitamin supplements may have harmful effects. 
People who smoke may be at increased risk of lung 
cancer if they take β carotene,7 8 and vitamin E sup-
plements may increase risk of heart failure in people 
with diabetes or vascular disease.9
While antioxidant vitamin supplements cannot be 
recommended as a public health measure to reduce 
the incidence of age related macular degeneration, 
people with early stage disease may benefit from sup-
plements containing vitamin C, vitamin E, β carotene, 
and zinc.10 The recommended combination and doses 
of antioxidant vitamins and minerals is found in only a 
few commercial supplements and should be taken on 
specialist advice,11 with appropriate consideration of 
the possible benefits and harms for the individual.
Do other options exist for primary prevention of 
age related macular degeneration? The strongest risk 
factors for this condition—age and genetic factors—are 
not preventable, although genetic research will provide 
new insights into the causes of the disease and there-
fore its prevention. High concentrations of polyunsatu-
rated fats are found in the retina, but evidence for a 
protective effect of dietary fatty acids in this condition 
is inconsistent.12 Smoking is the only preventable risk 
factor that has been associated with the condition in 
most observational studies.13 Currently, reducing the 
prevalence of smoking is probably the most effective 
method of reducing the population burden of this 
 common cause of visual loss in older people.
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Data sources and performance measurement
Measuring outcomes is necessary but difficult to get right
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In this week’s BMJ, Westaby and colleagues compare the 
value of two sources of data for determining mortality 30 
days after congenital cardiac surgery—hospital episode 
statistics (HES) and the central cardiac audit database.1 
They find that the central cardiac audit database is more 
complete than HES, but that individual centres need 
investment to improve the completeness and accuracy of 
their data. Their investigation follows a study published 
in the BMJ in 2004 that used HES to compare mortality 
from congenital heart surgery in different UK centres.2 
The study suggested that Oxford had significantly higher 
mortality than the national average, and the results were 
reported widely by the media. So have we learnt any-
thing new about the relative value of routinely collected 
versus specifically collected sources of data?
Routinely collected patient data are regularly ana-
lysed to investigate outcome. Equally regularly the 
results are contested by the specifically collected data-
set, which is often designed to measure the very thing 
being looked for. So why use routinely collected data to 
draw clinical conclusions at all? The advantages include 
pragmatism, wide coverage, low cost, and easy access. 
The disadvantages include superficial or inaccurate 
coding and potentially damaging generalisations.
HES data from the National Health Service (NHS) 
are widely used to produce outcome information and 
more recently to publicise differences between hospi-
tals. Data produced for administrative and financial 
purposes that are centred on the organisation not the 
patient may never be as complete as data derived 
from clinicians.
Huge datasets also invite misuse of statistical method—
the significance of correlations is a product of the number 
of data points, not necessarily its relative importance. 
Chance findings will occur if many tests are done on 
the same data; association is not the same as causality. 
Nonetheless, the sheer scale of the HES database makes 
it attractive and it has become a rich source of hypoth-
esis generation and evidence on outcomes. The database 
has been used to investigate associations between case 
volume and outcome (for example, oesophagectomy3 
and repair of aortic aneurysms4), to search for potentially 
useful predictors of outcome (for example, excess mortal-
ity associated with delay in operation after hip fracture5), 
to carry out quasilongitudinal studies to track changes 
in outcome related to changes in clinical practice (for 
example, acute urinary retention and prostatectomy,6 fol-
low-up after emergency admission,7 and changes in mor-
tality after paediatric cardiac surgery2), and increasingly 
to predict individual outcomes in patients at high risk.
Results that conflict with HES data have often been 
reported—for example, the relation between hospital vol-
ume and outcome8 9 and the predictive factors for poorer 
outcome in certain patients.10 This is not just a contest of 
science and statistics but of politics, hearts, and minds. As 
Westaby and colleagues note, the media rapidly picked 
up on the conclusion based on HES data that Oxford 
had significantly higher mortality after paediatric cardiac 
surgery than the national average.
While recognising that there are problems in spe-
cial datasets too—timescales and numbers of episodes 
are often smaller, making it more likely to miss a rare 
event or true difference, and collecting outcome data 
on your own performance may bias the case mix of 
patients selected for intervention—Westaby and col-
leagues conclude that HES data should not be used 
for comparisons within specialties.
Patients do not necessarily trust official data sources.11 
We need to know if they will trust information collected 
by doctors who analyse their own data and claim that 
their performance is sound. The NHS has recently 
appointed a new medical director, Professor Sir Bruce 
Keogh, who is famous for his leadership of British cardi-
othoracic surgeons in measuring outcomes and making 
them public. This appointment sends a clear signal to 
staff, the public, and the media about the importance of 
measuring outcomes.
It is unclear how much patients change their choice 
of provider based on such knowledge, or how much 
employers manage their clinical staff with an eye on 
comparative performance, however intuitively it seems 
important. With all its potential problems, HES has 
more to offer than league tables of performance. Better 
knowledge will flow from a collaboration of all sound 
analyses, based on complete data, that are accurately 
coded by clinicians who have an interest in the out-
come. This can only lead to more complete and contex-
tualised data being released into the public domain. 
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Participation in mammography screening
Women should be encouraged to decide what is right for them, rather than being 
told what to do
In April 2007, the American College of Physicians—the 
largest medical specialty society in the United States—
issued new guidelines on screening mammography for 
women aged 40-49. Rather than calling for universal 
screening, the guidelines recommend that women 
make an informed decision after learning about the 
benefits and harms of mammography.1
The last time a major US policy organisation made 
such a recommendation all hell broke loose. In 1997, 
a consensus panel of the National Institutes of Health 
concluded “that the data currently available do not 
warrant a universal recommendation for mammogra-
phy for all women in their forties. Each woman should 
decide for herself whether to undergo mammography.” 
This recommendation generated intense reactions in 
the press, public, and government.2 Most stories in 
the press suggested that women should be screened 
and others directed anger at the panel for “failing” 
to recommend screening. The panel’s chair was sum-
moned before congress, and a US senate resolution in 
favour of screening was unanimously passed—a rare 
act of bipartisanship. After a few months of intense 
political pressure, the National Cancer Institute con-
travened the panel’s conclusions and recommended 
that women in their 40s should be screened.
In contrast, the reaction to the recent guidelines was 
muted. The press carried a few stories—a few of which 
were critical—but there were no senate resolutions and 
no hearings to cross examine the leadership of the 
American College of Physicians.
The possible reasons for these dramatically different 
reactions are that the American College of Physicians 
may not have the same visibility as the National Insti-
tutes of Health panel; journalists and readers may be 
tired of the mammography debate; and politicians 
may be preoccupied with other matters. But a more 
positive explanation is that the public and profession 
increasingly accept that cancer screening has both 
benefits and harms. Perhaps we are finally moving 
beyond the debate about what women should do and 
are ready to focus on how to help women make the 
best decision for themselves.
So how can clinicians help? The first step—exempli-
fied by the recent guideline—is to acknowledge that 
women face a real choice. Screening entails trade-offs 
that are hidden by slogans such as “If you haven’t had 
a recent mammogram, you may need more than your 
breasts examined.” These messages are meant to per-
suade women to do what is right, as decided by the 
people who write them. But no right choice exists, 
because screening has mixed effects—some women will 
benefit (by avoiding death from breast cancer) but oth-
ers will be harmed. So the next step is to ensure that 
women understand what is likely to happen if they do 
or do not undergo screening.
The table shows estimates of the benefits and harms 
of screening mammography for women in their 40s and 
(for context) older women. Despite the wealth of pub-
lished literature, the numbers are still controversial, and 
any of the figures could be criticised. The table is not 
meant to be the final word on mammography but to con-
vey the order of magnitude of its effects. Furthermore, 
the data are based on averages, so the risks will be differ-
ent for women at high risk (such as those with a strong 
family history of early breast cancer). And of course, the 
numbers are only a start. If we seriously want to promote 
informed decisions, we must ensure that women under-
stand the data and have some context for judging how 
big (or small) these numbers are.10 11
The main benefit of screening is to avoid death from 
breast cancer. The relative risk of death from breast 
cancer for women who are screened is 0.85 for those in 
their 40s and 0.78 for those 50 and older.4 These figures 
may underestimate the efficacy of screening because 
Summary of data on benefits and harms of screening mammography every 1-2 years for 10 years
Benefits and harms
Age group of women (years)
                        40-49            50-69
Benefits
10	year	risk	of	death	from	breast	cancer*:
	 No	screening 3.3/1000	(0.33%) 8.9/1000	(0.89%)
	 Screening 2.5/1000	(0.25%) 6.0/1000	(0.6%)
Avoidance	of	death	from	breast	cancer 0.8/1000	(0.08%) 3/1000	(0.30%)
Harms
Patient	has	at	least	one	false	positive	screening	examination	that	results	in	additional	testing3 100-500/1000	(10-50%) 100-500/1000	(10-50%)
Patient	has	at	least	one	false	positive	screening	examination	that	results	in	unnecessary	diagnosis	
and	treatment	for	breast	cancer†
2-5/1000	(0.25-0.5%) 3-9/1000	(0.30-0.90%)
*The	10	year	chance	of	dying	from	breast	cancer	for	American	women	aged	40-49	and	50-69	(2002-4)	came	from	the	National	Cancer	Institute.	We	calculated	
the	risk	for	the	two	sets	of	women	using	the	risk	reduction	of	mammography	for	each	age	group4	after	adjusting	for	non-compliance	in	trials5	6	and	national	
estimates	of	mammography	uptake	in	each	age	group	about	10	years	earlier	according	to	the	National	Center	for	Health	Statistics.	This	approach	assumes	
that	the	total	risk	of	death	from	breast	cancer	is	the	weighted	average	of	the	risks	faced	by	women	who	are	and	are	not	screened.
†We	applied	estimates	of	the	proportion	of	screen	detected	cancers	that	are	overdiagnoses	(low	10%,7	high	30%8)	to	the	rate	of	screen	detected	breast	
cancers	in	trials	of	women	≥555	and	those	40-49.9
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of non-compliance in the trials; when we adjusted the 
relative risks for compliance the figures were 0.76 for 
younger women5 and 0.67 for older women.6 In the 
US, this means that for every 1000 women screened, 
over the next 10 years less than one life will be “saved” 
for younger women and about three lives will be saved 
for older women. Expressed differently, screening of 
women who are 50 or older improves the chance of 
not dying from breast cancer in the next 10 years from 
about 991/1000 to 994/1000.
Screening has several harms, including false positives 
and overdiagnosis. False positives are the most familiar to 
women and to doctors—abnormalities detected at mam-
mography often cause women to undergo repeat testing 
(or perhaps biopsy) to rule out cancer. The table shows a 
range for false positives because thresholds for deciding 
that a mammogram is abnormal differ greatly among 
mammographers and across settings (recall rates are 
much lower in the United Kingdom than in the US12).
False positives cause short term anxiety, inconven-
ience, and sometimes unnecessary biopsies, but we 
think that overdiagnosis is the most important harm of 
screening. Overdiagnosis is the detection of lesions that 
meet the pathological criteria for cancer but would not 
progress to cause symptoms or death. Such lesions lead 
to overtreatment. Because we do not know which can-
cers are overdiagnoses, we treat everybody. But women 
who are overdiagnosed can only be harmed by treat-
ment—they cannot benefit because no treatment was 
needed. Harms include disfiguring surgery, side effects 
of chemotherapy or hormonal therapy (such as nausea, 
fatigue, and hair loss), and injury from radiation.
Overdiagnosis is a counterintuitive phenomenon, 
and few women know about it.13 Because we cannot 
identify overdiagnosis during life, we do not hear sto-
ries from women harmed in this way by screening 
(in contrast, we routinely hear stories from women 
whose lives were “saved” by screening). But once 
informed about the possibility of overdiagnosis, most 
women say they would factor it into their decision 
about screening.13
Estimating the chance of overdiagnosis is challeng-
ing as it cannot be measured directly. Screening trials 
consistently show an excess of breast cancer diag-
noses in the intervention group, which does not go 
away with time, making it possible to estimate the 
proportion of screen detected breast cancers that are 
overdiagnoses. We used a range of published data to 
calculate the numbers shown in the table.7 8
The new guideline is an improvement because it 
integrates informed decision making into policy rec-
ommendations—a refreshing change in a field domi-
nated by soundbites and slogans. But why should this 
advance be limited to women in their 40s? And why 
just American women (only women over 50 are rou-
tinely invited for mammography in the UK)? Whether 
a woman is in her 40s or older—on either side of the 
Atlantic—screening for breast cancer involves bene-
fits and harms. Rather than telling women what they 
should do, policy makers should encourage women 
to make a decision that is right for them.
All references are on bmj.com
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A recent Cochrane review has updated our knowledge 
about screening asymptomatic people for abdominal 
aortic aneurysm, with respect to their mortality, subse-
quent treatment for the aneurysm, and the cost effec-
tiveness of screening.1 Four completed randomised 
controlled studies—Chichester, Viborg, Western Aus-
tralia, and the multicentre aneurysm screening study 
(MASS)—with 127 891 men and 9342 women (only 
the Chichester trial included women) aged from 65-
83 years were included to a cut-off date of 26 January 
2007. This excluded the more recent seven year fol-
low-up of men in MASS.2 Acceptance rates (of people 
agreeing to be screened) ranged from 63.1% (Western 
Australia) to 80.2% (MASS).
In men aged 65-79 years screening significantly 
reduced the risk of mortality related to aneurysm (rela-
tive risk 0.53 (confidence interval 0.42 to 0.68). This was 
achieved at the expense of doubling the rate of aneu-
rysm surgery. However, for studies in men, the review 
reported no significant reduction in all cause mortality. 
Although the Western Australia trial found a reduction 
in all cause mortality (from the time of screening and 
not randomisation), the authors note that the interval 
between randomisation and screening could have intro-
duced a bias, such that screening did not account for the 
reduction. However, the recent update from MASS also 
hints at a possible benefit in all cause mortality in men 
who were screened (estimated hazards ratio 0.96, 95% 
confidence interval  0.93 to 1.00),2 so a further update of 
the Cochrane review may be needed.
MASS produced a cost effectiveness analysis at four 
years with 47 fewer deaths from aneurysm equating to 
£28 400 (€42 000; $58 000) per life year gained and 
£36 000 per quality adjusted life year. At seven years 
this had fallen to £12 334 per life year gained2 and is 
likely to fall even further after 10 years. The Viborg 
trial derived a very different figure (£620 per life year 
saved), and the reason for this disparity seems opaque, 
although health economists should be able to shed 
some light on the reasons for the disparity.
The trials have provided evidence to suggest that 
screening in itself does not impair quality of life,3 4 
although this is not covered in the Cochrane review.
Data are still lacking on the potential benefits or 
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harms and costs for screening women, although at 
least one group suggests it may be cost effective5 and 
the screening of high risk women was supported by 
the current president of the Society for Vascular Sur-
gery in the United States.6
All these data are supportive of a national screen-
ing programme, and at a time when the NHS is con-
sidering the cost implication of establishing such a 
programme for men aged 65 years, the seven year fol-
low-up data from MASS with the lower cost per life 
year gained are especially timely.
Correctly, the mood is in favour of aneurysm screen-
ing, but the following policy problems still need to be 
tackled. How can screening uptake be improved in 
those at highest risk (such as those in the lowest socio-
economic groups)? How can screening be refused to 
men older than 65 years and women at highest risk 
(such as smokers and those with a strong family history 
of aneurysm)? How and where should patients with 
screen detected aneurysms be managed?
All the screening trials, as well as other randomised 
trials of aneurysm treatment, report operative mortality 
of about 5% for open elective surgery (as used in all the 
screening trials) for aneurysms ≥5.5 cm in diameter, the 
general threshold for intervention. Randomised trials 
show that operative mortality is lower from endovascu-
lar repair (<2%) than from open repair (<5%), although 
endovascular repair costs more.7-9 Not only may medical 
treatment, including statins, further improve operative 
mortality and life expectancy in those found to have 
abdominal aortic aneurysms,10 there is now the expecta-
tion that statins and other new treatments will slow the 
growth of small aneurysms found by screening.11 12
Screening should do no harm. However, a recent 
evaluation of administrative and clinical databases look-
ing at predictors of risk of death in hospital suggests 
that in England the in-hospital mortality for non-rup-
tured abdominal aortic aneurysm repair is 10.2%.13 A 
systematic review using the same dataset emphasised 
that although the worst mortality rates were from low 
volume hospitals, excellent results were achievable in 
occasional low volume hospitals.14
These data show that operative results of hospitals 
are central to whether screening saves or loses lives. We 
must tackle how acceptable mortality can be achieved 
across the whole country, perhaps using the protocols 
that led to such an acceptable mortality in the 41 EVAR 
trial centres.7 9 Without such safeguards, screening for 
abdominal aortic aneurysm may not bring the expected 
results and instead may cause regret about the new 
screening programme.
All references are on bmj.com
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Another fine mess the Department of Health has got doctors into
nEWS, pp 737, 738
VIEWS & REVIEWS, p 775
Tony Delamothe deputy 
editor, BMJ, london WC1H 9JR 
tdelamothe@bmj.com
competing interests: tD’s 
wife qualified in the European 
Economic Area and shortlisted and 
interviewed for the london Deanery.
Provenance and peer review: 
Commissioned; not externally 
peer reviewed.
BMJ 2007;335:733-4
doi: 10.1136/bmj.39364.512685.80
“Although a deeply damaging episode for 
British medicine, from this experience must 
come a recommitment to optimal standards of 
postgraduate medical education and training. 
This can only occur if a new partnership is struck 
between the profession and the DH [Department 
of Health], and between Health and Education. 
Each constituency has been found wanting thus 
far. In future, each must play its part. An aspiration 
to clinical excellence in the interests of the health 
of the population must be paramount.”
So concludes Professor Sir John Tooke’s inquiry into 
Modernising Medical Careers (MMC).1 2 This ini-
tiative, “an honest attempt to accelerate training and 
assure the fundamental abilities of the next generation 
of doctors” almost foundered over the failure of its 
main component, the centralised selection into run-
through specialist training. In response, the govern-
ment announced an independent inquiry into MMC, 
the interim report of which was released this week. 
While Tooke’s report runs through the reasons for 
the failure of the medical training application service 
(MTAS), these have been extensively covered in a pre-
vious report.3 Sir John’s canvas was much wider. His 
panel “explored the background and context—in medi-
cal terms the predisposing or aetiological factors—that 
may have contributed to the perceived problems with 
MMC, rather than simply focusing on MTAS.”
So, what went wrong? Wherever Sir John shone his 
torch he found debilitating vagueness and frailty. He 
found no evidence of a consensus on the educational 
principles guiding postgraduate medical training and 
that mechanisms for creating such a consensus are 
weak. The management of postgraduate training is 
hampered by unclear principles, a weak contractual 
base, a lack of cohesion, a fragmented structure, and, 
in England, deficient relationships between academia 
and service. No consensus exists over doctors’ roles 
at various career stages, which hampers planning of 
the medical workforce. A vacuum exists in policy 
regarding the potentially massive increase in trainee 
numbers. And so on.
At the press conference launching his report, Sir 
John refused to name and shame the guilty parties, 
but because he listed governance and risk manage-
ment as most at fault they are most likely to reside at 
the Department of Health. In mitigation, responsibil-
ity for MMC was split between two people and the 
biggest headaches—MTAS4 and the surfeit of eligible 
international medical graduates5—were outside the 
responsibilities of both of them. 
This week, the government announced that there 
would be no national IT system for job applications 
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next year and that it was launching a consultation 
exercise over training jobs for medical graduates from 
outside the European Economic Area.6 How had the 
stewardship of medical training deteriorated to such an 
extent at the Department of Health? Benign or malign 
neglect? Conspiracy to further deprofessionalise doc-
tors or cock-up? Once again Sir John would not be 
drawn, but the manifest organisational failures of the 
department would suggest that conspiracy was beyond 
its skill set.
The bottom line is that the department has wrested 
control of doctors’ training from the medical profes-
sion and has proved itself unequal to the task. One 
of Tooke’s “corrective actions” concerns the Post-
graduate Medical Education and Training Board, 
set up to regulate postgraduate medical education in 
the wake of the Bristol inquiry. He wants it merged 
with the General Medical Council, which already 
regulates two of the three components of medical 
education (undergraduate education and continuing 
professional development). Crucially, “it is a body 
that reports to Parliament, rather than through the 
monopoly employer [Department of Health].”
Doctors don’t emerge unscathed. “Forensic” 
analysis of meeting records shows they were well 
represented on the various delivery and advisory 
boards—one figure in the report lists an alphabet soup 
of 19 different representative bodies, with their dates 
of attendance. But in sum their influence was “sub-
optimal.” Their frequent calls for trialling and delay 
went largely unheeded, and they reported being 
deterred from questioning policies. On occasion, 
they weakened their impact by speaking up for their 
individual consistencies rather than for the profession 
as a whole, according to the report.
The report recommends that the medical profes-
sion urgently needs to develop a way of providing 
coherent advice on matters that affect the entire pro-
fession, without giving details of what this might look 
like. And it wants a consensus on the role of doctors 
to be agreed by the end of 2008. Sir John admits it’s a 
tall order, but it would coincide with the 150th anni-
versary of the Medical Act, something that obviously 
appeals to a doctor who quotes William Osler and 
medical historian Roy Porter in his foreword.
For the doctor on the ward or in the clinic the 
biggest changes will be those recommended for the 
structure of postgraduate training. The need for a 
broad based beginning, flexibility, and the promo-
tion of excellence recur like a mantra throughout the 
report. Sir John says this part of the report was heav-
ily influenced by the workshops he held throughout 
the United Kingdom, which involved 450 trainee 
doctors. They said that they wanted to be much bet-
ter than “just good enough” for their jobs (hence the 
report’s title, Aspiring to Excellence).
The report recommends that the link between 
foundation years one and two is broken, allowing 
the second foundation year to become the first of a 
three year core training programme (along with the 
current first and second years of specialist training 
HST1 and ST2). Up to half a dozen defined core 
programmes (including ones in surgery, medicine, 
and general practice) are envisaged, which would 
involve six appointments of six months each. These 
core programmes would serve as stems for subse-
quent specialty training.
Entry into higher specialty training after the core 
programme would be based on marks obtained in 
national assessment centres for the specialty in ques-
tion, together with structured CVs and interviews for 
shortlisted candidates at deanery level.
General practice training “must be extended to five 
years to assure the skill base of that part of the medi-
cal workforce that is going to become increasingly 
important, with rising longevity, increasing co-mor-
bidity, and shifts of care to the community.” And 
the future of doctors in fixed term specialty training 
appointments and in the non-consultant career grade 
needs to be sorted out.
If Tooke’s recommendations for the early years of 
training sound familiar it is because they resemble the 
proposals for senior house officer training set out in 
Unfinished Business, a consultation paper dating from 
2002. Its principles were that training in these early 
years should begin with a broad based programme 
and be flexible to trainees’ needs, providing oppor-
tunities to leave and re-enter. However, a subsequent 
document reported that “thinking had moved beyond 
the basic specialist programmes foreseen in Unfinished 
Business” towards a single “run-through approach,” 
a shift recently discussed in these pages.7 Tooke’s 
comment, “although whose thinking and with what 
authority is not entirely clear,” could stand as his 
verdict on this whole sorry chapter of Modernising 
Medical Careers.
And as to the next chapter? Richard Hayward 
captures the challenges well in his personal view 
this week, “the MTAS fiasco (for which all parties 
must share responsibility) stands as a dire warning to 
government and medical profession alike of trying 
to reform health care without cooperation between 
the two. Expect the current rocky ride to continue 
until and unless the government and the community 
of independent medical practitioners find common 
ground—something that will require a shift of culture 
on both sides if the NHS is really to benefit.”8 Tooke 
has provided the roadmap for postgraduate medical 
education and training.
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